VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has decided to advance its investigation of NP-120 (Ifenprodil) for IPF with cough as its key indication. As a result, the Company further announces…


Previous articleNuminus Now Offers Ketamine-Assisted Therapy in Toronto
Next articlePsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application Accepted